New and Upcoming Therapeutics/Resources.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 14
- Publication type:
- Article
Works matching IS 15430790 AND DT 2024 AND VI 22
Results: 100
1
2
Building a High-Volume Multidisciplinary NET Program.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 13
- Publication type:
- Article
3
Preliminary Safety and Efficacy Data of [<sup>212</sup>Pb]VMT-a-NET in Somatostatin Receptor 2-Expressing NETs.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 12
- Publication type:
- Article
4
Cabozantinib Versus Placebo for Advanced NETs After Progression on Prior Therapy: CABINET Trial/Alliance A021602.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 11
- Publication type:
- Article
5
Safety of <sup>177</sup>Lu-Dotatate Treatment in Patients With Advanced NETs and Extensive/Innumerable Bone Metastases.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 10
- Publication type:
- Article
6
First-Line Efficacy of <sup>177</sup>Lu-Dotatate in Gastroenteropancreatic NETs by Tumor Grade and Primary Origin: Phase 3 NETTER-2 Subgroup Analysis.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 9
- Publication type:
- Article
7
The Great Debate: NETTER-2 - <sup>177</sup>Lu-Dotatate: 1<sup>st</sup> Line or 2<sup>nd</sup>+ for Ki-67 >10%.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 6
- Publication type:
- Article
8
NET Year in Review.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 2
- Publication type:
- Article
9
Targeted Immunotherapy in the Treatment of Childhood and Adolescent Classic Hodgkin Lymphoma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 10, p. 520
- By:
- Publication type:
- Article
10
The Emergence of Bispecific T-Cell Engagers in the Treatment of Follicular and Large B-Cell Lymphomas.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 10, p. 510
- By:
- Publication type:
- Article
11
Circulating Tumor DNA in Early-Stage Breast Cancer: Ready for the Clinic?
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 10, p. 507
- By:
- Publication type:
- Article
12
Incorporating PSMA PET Imaging Into the Treatment Plan for Newly Diagnosed and Recurrent Prostate Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 10, p. 497
- By:
- Publication type:
- Article
13
Choosing Between CAR T-Cell Therapy and Pirtobrutinib in Double-Refractory CLL.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 10, p. 494
- By:
- Publication type:
- Article
14
The Use of Zenocutuzumab for NRG1 Fusion-Positive Tumors.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 10, p. 487
- By:
- Publication type:
- Article
15
What Will Be the Next Partner for Combination Immunotherapy With Nivolumab and Ipilimumab?
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 10, p. 483
- By:
- Publication type:
- Article
16
Who's Your Advocate?
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 10, p. 470
- By:
- Publication type:
- Article
17
Slide Library.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 13
- Publication type:
- Article
18
The Importance of the Shared-Care Approach When Triplet Therapy Is Selected in mHSPC: Q&A.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 11
- By:
- Publication type:
- Article
19
A Shared-Care Approach to the Management of Patients With mHSPC: The Oncology Perspective.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 9
- By:
- Publication type:
- Article
20
A Shared-Care Approach to the Management of Patients With mHSPC: The Urology Perspective.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 8
- By:
- Publication type:
- Article
21
Selecting Patients With Metastatic Hormone-Sensitive Prostate Cancer for Combination Therapy.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 3
- By:
- Publication type:
- Article
22
Targeted Therapy in Prostate Cancer: Beyond PSMA.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 9, p. 423
- Publication type:
- Article
23
Should Ponatinib Be the Standard-of-Care Tyrosine Kinase Inhibitor in Ph+ ALL?
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 9, p. 413
- Publication type:
- Article
24
Recombinant ADAMTS13 Concentrate in Thrombotic Thrombocytopenic Purpura.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 9, p. 430
- Publication type:
- Article
25
Tackling the Cancer Drug Shortage.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 9, p. 426
- Publication type:
- Article
26
Does Combination Menopausal Hormone Therapy Increase the Risk of Breast Cancer?
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 9, p. 433
- Publication type:
- Article
27
Treatment of Unresectable and Resectable Stage IV Colorectal Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 9, p. 455
- By:
- Publication type:
- Article
28
Nivolumab 3 mg/kg and Ipilimumab 1 mg/kg in Molecularly Selected Patients With Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 16
- Publication type:
- Article
29
Open-Label, Multicenter Randomized Trial of Radium-223-Docetaxel Versus Docetaxel-Radium-223 Sequence in Metastatic Castration-Resistant Prostate Cancer With Prospective Biomarker Evaluation (RAPSON Study).
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 15
- Publication type:
- Article
30
Phenotypic and Genomic Characterization of De Novo Metastatic Prostate Cancer: An Ancillary Study of the PEACE-1 Phase III Trial.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 14
- Publication type:
- Article
31
Decipher mRNA Score for Prediction of Survival Benefit From Docetaxel at Start of Androgen-Deprivation Therapy for Advanced Prostate Cancer: An Ancillary Study of the STAMPEDE Docetaxel Trials.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 12
- Publication type:
- Article
32
Adding Metformin to Androgen-Deprivation Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer: Overall Survival Results From the Multi-Arm, Multi-Stage, Randomized Platform Trial STAMPEDE.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 11
- Publication type:
- Article
33
Cabozantinib Plus Atezolizumab Versus 2nd Novel Hormonal Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Results of the Phase III, Randomized, CONTACT-02 Study.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 9
- Publication type:
- Article
34
A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Enzalutamide Versus a Combination of Radium-223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Patients With Bone Metastatic Castration-Resistant Prostate Cancer: First Results of EORTC-GUCG 1333/PEACE-3.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 8
- Publication type:
- Article
35
Efficacy and Safety of Darolutamide Plus Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 6
- Publication type:
- Article
36
Management Options for Node-Positive Muscle-Invasive Bladder Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 8, p. 392
- By:
- Publication type:
- Article
37
Refining the Standard of Care in Immune Thrombotic Thrombocytopenic Purpura.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 8, p. 381
- By:
- Publication type:
- Article
38
Management of Oligometastatic Hormone-Sensitive Prostate Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 8, p. 370
- By:
- Publication type:
- Article
39
Is Luspatercept the New Standard of Care in Transfusion-Dependent Low-Risk Myelodysplastic Syndromes?
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 8, p. 367
- By:
- Publication type:
- Article
40
Doublet vs Triplet Combinations for Frontline Treatment of Chronic Lymphocytic Leukemia.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 8, p. 364
- By:
- Publication type:
- Article
41
The Emerging Role of Immunotherapy-Based Strategies in Nonmetastatic Colorectal Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 8, p. 356
- By:
- Publication type:
- Article
42
The Global Cardio-Oncology Registry.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 8, p. 348
- By:
- Publication type:
- Article
43
Incentive Planning.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 8, p. 341
- By:
- Publication type:
- Article
44
HER2-Targeted Therapies in Non--Small Cell Lung Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 7, p. 334
- By:
- Publication type:
- Article
45
Can We Cure Ph+ ALL Without Chemotherapy or Transplant?
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 7, p. 328
- By:
- Publication type:
- Article
46
STING Activators in Cancer Care.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 7, p. 331
- By:
- Publication type:
- Article
47
Clonal Hematopoiesis: Malignant Implications, Extrahematologic Manifestations, and Management.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 7, p. 320
- By:
- Publication type:
- Article
48
Q&A: Barriers to Testing for NTRK Fusions in Metastatic Lung and Thyroid Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 16
- By:
- Publication type:
- Article
49
Management of Patients with NTRK Fusion-Positive Thyroid Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 9
- By:
- Publication type:
- Article
50
Management of Patients with NTRK Fusion-Positive Lung Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 5
- By:
- Publication type:
- Article